What services does JCC Group provide for pharmaceutical and biologics manufacturers?

JCC Group offers end-to-end regulatory consulting services for pharmaceutical and biologics companies, including 21 CFR Part 211 cGMP compliance, Quality Management System (QMS) design, validation strategy, FDA inspection readiness, supplier qualification, data integrity assessments, and harmonization with ICH international standards (Q7, Q8, Q9, Q10, and Q11). Our consultants partner with clients across the full product lifecycle — from facility start-up and clinical-stage manufacturing through commercial production and post-approval changes.

What types of companies does JCC Group work with?

We support a broad spectrum of clients, including emerging biotech startups, contract manufacturers (CMOs/CDMOs), mid-size pharmaceutical companies, global drug manufacturers, biologics and cell & gene therapy developers, and international manufacturers exporting to the U.S. market. Whether you are launching your first product or managing a multi-site global operation, our services scale to fit your needs.

What is 21 CFR Part 211, and who must comply?

21 CFR Part 211 establishes the FDA's Current Good Manufacturing Practice (cGMP) requirements for finished pharmaceuticals. It applies to any company involved in manufacturing, processing, packaging, labeling, or holding human and veterinary drug products distributed in the United States — including drug substance and drug product manufacturers, contract facilities, and repackagers.

How does JCC Group help companies achieve 21 CFR Part 211 compliance?

We provide comprehensive support including cGMP gap assessments, QMS design and implementation, SOP and documentation development, equipment qualification (IQ/OQ/PQ), process and cleaning validation, quality control laboratory compliance, change control programs, CAPA systems, and mock FDA inspections. Our team builds compliance programs tailored to your operations — not generic templates.

Does JCC Group support biologics manufacturers under 21 CFR Part 211?

Yes. While biologics are also governed by 21 CFR Part 600-series regulations, Part 211 still applies to many aspects of biologic drug product manufacturing. We support biologics manufacturers across monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, and biosimilars — addressing both small-molecule and large-molecule complexities.

What are ICH guidelines, and why do they matter?

The International Council for Harmonisation (ICH) develops globally recognized standards for pharmaceutical quality, safety, and efficacy. Compliance with ICH guidelines — especially Q7 (API GMP), Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), Q10 (Pharmaceutical Quality System), and Q11 (Drug Substance Development) — is essential for companies seeking global market access and harmonized regulatory approval across the U.S., EU, Japan, and other ICH regions.

How does JCC Group help companies align with ICH standards?

Our consultants integrate ICH principles into every aspect of our consulting work. We design Pharmaceutical Quality Systems aligned with ICH Q10, implement quality risk management frameworks per ICH Q9, support development activities under Q8/Q11, and ensure API manufacturing aligns with ICH Q7 — enabling clients to meet both FDA expectations and global harmonized requirements simultaneously.

Can JCC Group build a Quality Management System (QMS) from scratch?

Absolutely. We design and implement complete Quality Management Systems for new facilities, startups, and companies transitioning from clinical-stage to commercial manufacturing. Our QMS deliverables include Quality Manuals, SOPs, work instructions, forms, Master Production Records, Batch Production Records, change control systems, and integrated documentation control platforms.

Does JCC Group provide ongoing QMS maintenance and support?

Yes. Beyond initial implementation, we offer long-term advisory services to keep your QMS current with evolving regulations, support periodic management reviews, conduct internal audits, manage CAPA effectiveness checks, and provide regulatory intelligence updates. Many clients engage us as their long-term regulatory partner rather than a one-time consultant.

What happens during a mock FDA inspection conducted by JCC Group?

Our mock inspections replicate real FDA methodology — including facility walkthroughs, document reviews, employee interviews, and front-room/back-room dynamics. We assess your operations against 21 CFR Part 211, your QMS, and applicable ICH standards, then deliver a detailed report with prioritized findings, root cause insights, and clear remediation recommendations.

Can JCC Group help if we received a Form 483 or FDA Warning Letter?

Yes — rapid-response remediation is one of our core specialties. Our team conducts immediate root cause investigations, develops comprehensive CAPA plans, drafts written responses that meet FDA expectations, and manages the remediation process from start to finish. We have helped clients successfully close significant findings and restore compliance under tight deadlines.

New Ingredient Notification - J&J Consulting Group- FDA Regulatory Compliance

New Ingredient Notification: Preparation & Submission to the FDA

A complete compliance guide for nutraceutical, dietary supplement, and food ingredient manufacturers — and how JJCC Group helps you meet every FDA requirement.

Bringing a new ingredient to market in a regulated industry is one of the most consequential — and most scrutinized — steps a manufacturer, distributor, or brand owner can take. Before a novel substance can lawfully enter interstate commerce in a dietary supplement, conventional food, or food-contact application, the U.S. Food and Drug Administration (FDA) expects to be informed, and in many cases must affirmatively review the safety basis for that ingredient. Getting this wrong can mean import refusals, warning letters, product seizures, and costly recalls. Getting it right requires a disciplined, evidence-driven submission built on the correct regulatory pathway. J&J Compliance Consulting Group (JJCC Group) prepares, assembles, and manages New Ingredient Notifications end-to-end, so your launch stays on schedule and on the right side of the law.

This page explains what a New Ingredient Notification is, which 21 CFR regulations govern each industry, who is legally responsible for filing, exactly what the notification must contain section by section, what counts as a “new ingredient,” and how JJCC Group delivers each piece of the package.

Understanding the Pathways: One Term, Several Regulations

“New Ingredient Notification” is an umbrella description. The exact filing, the deadline, and the controlling regulation depend entirely on how the ingredient will be used. A botanical destined for a capsule supplement follows a different route than the same botanical added to a beverage. JJCC Group’s first deliverable is always a pathway determination — confirming which regulation applies before a single page of the dossier is written.

Industry / Use	Filing Type	Governing 21 CFR
Dietary supplements / nutraceuticals	New Dietary Ingredient Notification (NDIN)	21 CFR 190.6 (FD&C Act § 413); 21 CFR Part 111 (cGMP)
Conventional food / beverage ingredients	GRAS Notification (voluntary)	21 CFR Part 170, Subpart E (170.30, 170.36)
Food additives (non-GRAS)	Food Additive Petition (FAP)	21 CFR 171.1; safety standard 21 CFR 170.3
Color additives	Color Additive Petition (CAP)	21 CFR Part 71 (FD&C Act § 721)
Food-contact substances	Food Contact Notification (FCN)	21 CFR Part 170, Subpart D (170.100–170.106)

Note: medical devices and pharmaceuticals follow entirely separate regimes (21 CFR Parts 210/211 for drugs, 820 for device quality systems, ISO 13485 for device QMS). JJCC Group advises across all of these, but “New Ingredient Notification” in the FDA sense centers on the food and supplement pathways above.

Nutraceuticals & Dietary Supplements: The NDIN (21 CFR 190.6)

Under section 413 of the Federal Food, Drug, and Cosmetic Act, a manufacturer or distributor must notify FDA at least 75 days before introducing into interstate commerce a dietary supplement that contains a new dietary ingredient (NDI) — one not present in the food supply as an article used for food in a form that has not been chemically altered. The procedural rule lives at 21 CFR 190.6. The notification goes to the Office of Dietary Supplement Programs (HFS-810), CFSAN, in College Park, Maryland.

The 75-day clock begins on FDA’s filing date (the date of receipt), and the agency will not disclose the existence of the notification for 90 days after filing. If the notifier submits a substantive amendment during review, FDA may reset the clock with a new filing date.

What is a “new dietary ingredient”?

A dietary ingredient is “new” if it was not marketed in the United States in a dietary supplement before October 15, 1994. The following typically trigger an NDIN:

Novel botanicals, extracts, or concentrates not previously sold in supplements before the cutoff date.
Synthetic or fermentation-derived versions of an ingredient where the manufacturing process chemically alters the substance.
New combinations, higher potencies, or new dosage forms that change identity or exposure.
Ingredients used previously in food but now chemically altered for supplement use.

When an NDIN is NOT required

Determining grandfathered status is a frequent point of dispute with FDA. JJCC Group builds the documentary record to support the chosen position before you commit to it.

Food & Beverage Ingredients: GRAS and Food Additive Routes

If the same ingredient is intended for a conventional food or beverage rather than a supplement, the NDIN does not apply. Instead, the substance must either be the subject of an approved Food Additive Petition under 21 CFR 171.1, or qualify as Generally Recognized as Safe (GRAS).

GRAS Notification — 21 CFR Part 170, Subpart E

GRAS status can be established through scientific procedures (21 CFR 170.30(b) — the same quantity and quality of evidence needed for food-additive approval, generally published studies) or, rarely, through common use in food before 1958 (21 CFR 170.30(c) and 170.3(f)). The GRAS Notification program is voluntary: a notifier informs FDA’s Office of Food Additive Safety (HFS-200) of its independent conclusion, and FDA issues a “no questions” letter, a letter ceasing evaluation, or an objection.

Food Additive Petition — 21 CFR 171.1

When safety cannot be generally recognized, a full FAP is required. Under 21 CFR 171.1(c), the petition must establish identity and composition, intended use and use levels, the intended technical effect, validated analytical methodology, full reports of safety studies, proposed tolerances where applicable, and an environmental assessment. FDA — not outside experts — makes the safety determination here.

Who Is Responsible for Preparing and Submitting?

For an NDIN, 21 CFR 190.6(a) places the obligation on the manufacturer or distributor of either the dietary supplement that contains the NDI, or of the NDI itself. A key trap: an ingredient supplier’s NDIN does not automatically cover the finished-product company. Unless the supplier’s prior notification specifically described the finished supplement and its conditions of use, the supplement manufacturer or distributor must file its own NDIN. JJCC Group maps this responsibility chain early so no party assumes someone else has “already filed.”

Dietary supplements: the NDI manufacturer, the finished-supplement manufacturer, or the distributor — each may need to file depending on coverage.
GRAS / food additives: the ingredient sponsor, manufacturer, or an authorized agent may submit; agents commonly file on the client’s behalf.
Signatory: 21 CFR 190.6(b)(5) requires the signature of a person designated by the manufacturer or distributor.

JJCC Group can serve as your authorized agent and U.S. point of contact, coordinate signatures, and manage all correspondence with FDA throughout the review window.

What the Notification Includes

For an NDIN, 21 CFR 190.6(b) specifies the mandatory contents. JJCC Group prepares each of the following components and assembles them into an FDA-ready dossier.

§	Required Element	How JJCC Group Delivers It
1	Notifier identity — name and complete address of the manufacturer/distributor [190.6(b)(1)]	We confirm the correct legal entity, designate the responsible signatory, and prepare a clean cover letter and administrative cover sheet.
2	Ingredient identity — name of the NDI; for botanicals, the Latin binomial and author citation [190.6(b)(2)]	We characterize the ingredient — specifications, identity testing, part of plant used, extraction solvent and ratio — and apply correct nomenclature so FDA can unambiguously identify the substance.
3	Product description — the supplement(s) containing the NDI: conditions of use, dose, label directions [190.6(b)(3)]	We document the finished-product formula, serving size, target population, and labeled conditions of use, and align the dossier to your intended marketing claims.
4	Safety basis — history of use or other evidence that the ingredient is reasonably expected to be safe, with full reprints of every cited reference [190.6(b)(4)]	We construct the safety narrative: literature review, history-of-use evidence, toxicology data, exposure assessment, and a margin-of-safety analysis — and supply full-text copies of every reference, as the regulation requires.
5	Signature of the designated person [190.6(b)(5)]	We coordinate the authorized signature and submit an original plus the required copies (or the accepted electronic format) to HFS-810.

For GRAS notices, the parallel structure under 21 CFR Part 170 Subpart E includes the GRAS exemption claim, identity and method of manufacture, dietary exposure, self-limiting levels, and the basis for the GRAS conclusion supported by a published safety dossier and, typically, an expert-panel consensus. JJCC Group builds the equivalent package and convenes or coordinates the qualified-expert panel where a scientific-procedures GRAS conclusion is used.

The JJCC Group New Ingredient Notification Program

Our service is structured so that every regulatory requirement maps to a concrete deliverable. We work within a cGMP-disciplined framework — SOPs, CAPA, validation, and data-integrity controls — so the evidence you submit is defensible and audit-ready.

Pathway determination. We confirm whether your ingredient requires an NDIN, GRAS Notification, FAP, FCN, or no filing at all — and whether grandfathered status applies.
Gap assessment. We inventory existing identity, manufacturing, and safety data against the controlling regulation and define exactly what is missing.
Ingredient characterization. Specifications, identity testing, manufacturing description, and impurity profiling consistent with 21 CFR Part 111 (supplements) or Part 117 / 171 expectations (food).
Safety dossier. Literature review, history of use, toxicology gap-filling, exposure modeling, and the reasonable-expectation-of-safety argument, with full reference reprints.
Dossier assembly & QC. We compile every section into an FDA-ready submission, quality-check it against the regulation, and confirm format and copy requirements.
Submission & agent representation. We file with the correct CFSAN office, act as your U.S. agent and point of contact, and manage the 75-day (NDIN) or review-period correspondence.
FDA response management. We draft responses to agency questions, manage any substantive amendments and clock resets, and advise on next steps after the response letter.

From a single ingredient launch to a full portfolio, JJCC Group converts a complex, deadline-driven regulatory obligation into a managed, predictable project. Contact JJCC Group through jjccgroup.org to scope your New Ingredient Notification and protect your path to market.